TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10084353

Group type: EXPERIMENTAL
Intervention: Consumer advocacy program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumer advocates
Number of subjects: 0
Study: 8030601

Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 10

Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 10
Study: 29580220

Group type: EXPERIMENTAL
Intervention: Trauma-focused online guided self-help (GSH)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Face-to-face trauma-focused cognitive behaviour therapy (TFCBT)
Number of subjects: 192
Study: 26846860

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering treatment
Number of subjects: 2069
Study: 25478237

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation over the left primary auditory cortex (verum group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment (sham group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls (n = 12)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation over the left primary auditory cortex
Number of subjects: 23
Study: 22441774

Group type: EXPERIMENTAL
Intervention: Rhythm-control
Number of subjects: 933

Group type: COMPARATOR
Intervention: Rate-control
Number of subjects: 933
Study: 20570361

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sub‐Tenon's anesthesia
Number of subjects: 60
Study: 18716735

Group type: EXPERIMENTAL
Intervention: Diepoxybutane 0.1 mug/ml
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.1 microg/ml
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Irradiation (300 rads)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Irradiation (400 rads)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mitomycin and rad4
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mean chromosomal breakage
Number of subjects: 27
Study: 16622371

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group intervention
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care plus information on self-care (information comparison group)
Number of subjects: 213
Study: 12727316

Group type: EXPERIMENTAL
Intervention: Brief and unobtrusive instrument to detect simulation and exaggeration in patients with whiplash syndrome.
Number of subjects: 100
Study: 10829398

Group type: EXPERIMENTAL
Intervention: HDBPM oscillometric sphygmomanometer
Number of subjects: 92
Study: 8800586

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (40-55% HRres)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (65-80% HRres)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Continuing participation in any regular exercise
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 126
Study: 1641050

Group type: EXPERIMENTAL
Intervention: Protocol I: 240 mg paracetamol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Protocol II: 500 mg paracetamol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Protocol III: 500 mg paracetamol plus 10 mg codeine
Number of subjects: 64
Study: 6381269

Group type: EXPERIMENTAL
Intervention: Proglumetacin 450 mg/day (150 mg in the morning, 300 mg in the evening)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day (placebo in the morning, 20 mg in the evening)
Number of subjects: 50
Study: 30610038

Group type: EXPERIMENTAL
Intervention: TMIT I (both PD‐L1‐positive tumor cells & CD8‐high TILs)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: TMIT III (PD‐L1‐positive tumor cells & CD8‐low TILs)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: PD‐L1 expression
Number of subjects: 479
Study: 27215455

Group type: EXPERIMENTAL
Intervention: CT guided radiofrequency ablation followed by intratumoral chemotherapy (RFA-ITC)
Number of subjects: 110
Study: 24758245

Group type: EXPERIMENTAL
Intervention: CPAP/PEEP of 6 cmH2O with FIO2 1.0
Number of subjects: 30

Group type: COMPARATOR
Intervention: No CPAP/PEEP with FIO2 1.0
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPAP/PEEP of 6 cmH2O with FIO2 0.8
Number of subjects: 30
Study: 22102090

Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 597
Study: 20679668

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 241

Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 241
Study: 18815843

Group type: EXPERIMENTAL
Intervention: Intervention (collaborative management by primary care-pharmacist teams)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control (usual primary care)
Number of subjects: 463
Study: 15902994

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12920428

Group type: EXPERIMENTAL
Intervention: Self-selected music therapy (n = 100)
Number of subjects: 198

Group type: COMPARATOR
Intervention: No music (Control group, n = 98)
Number of subjects: 198
Study: 10505693

Group type: EXPERIMENTAL
Intervention: VPA-985 (250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8941477

Group type: EXPERIMENTAL
Intervention: LysB28, ProB29-human insulin analogue (lispro)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 27
Study: 1752019

Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen (N2O/O2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air in oxygen (N2/O2)
Number of subjects: 10
Study: 6810843

Group type: EXPERIMENTAL
Intervention: Intravenous heparin sodium, 5,000 IU/6 hr
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 47
Study: 30068416

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study: 25632044

Group type: EXPERIMENTAL
Intervention: 5-minute mindful breathing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Listening (being listened to)
Number of subjects: 20
Study: 23904472

Group type: EXPERIMENTAL
Intervention: Individualised combined resistance and aerobic exercise intervention for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving only information about the benefits of exercise
Number of subjects: 40
Study: 22484799

Group type: EXPERIMENTAL
Intervention: arzoxifene 20 mg/day
Number of subjects: 9354

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9354
Study: 20380924

Group type: EXPERIMENTAL
Intervention: Dynamic speed limit system (basic roadside, advanced roadside, advanced in-car)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Advanced dynamic speed limit system
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dynamic speed limit systems
Number of subjects: 46

Group type: COMPARATOR
Intervention: Static speed limit system
Number of subjects: 46
Study: 18771352

Group type: EXPERIMENTAL
Intervention: FWGE (fermented wheat germ extract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (dacarbazine-based chemotherapy)
Number of subjects: 0
Study: 15821654

Group type: EXPERIMENTAL
Intervention: Arterial line leukocyte filter (Pall LeukoGuard 6)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without any filter
Number of subjects: 50
Study: 15328774

Group type: EXPERIMENTAL
Intervention: Standard Thai passages devoid of nasal consonants
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Standard Thai passages with a mixture of oral and nasal consonants
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Standard Thai passages full of nasal consonants
Number of subjects: 188
Study: 10832268

Group type: EXPERIMENTAL
Intervention: Brachial plexus block by low interscalenic tract (Group B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Brachial plexus block by armpit tract (Group A)
Number of subjects: 43
Study: 9104520

Group type: EXPERIMENTAL
Intervention: Propofol patient-controlled sedation (PCS) at a dose of 0.3 mg.kg-1, delay = three min (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anaesthetist-administered midazolam-fentanyl sedation (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol patient-controlled sedation (PCS)
Number of subjects: 40
Study: 8471416

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (2 mg kg‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (2.5 and 3 mg kg‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (4.5 and 6 mg kg‐1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate MF701 (all doses)
Number of subjects: 25
Study: 3524531

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (450 micrograms/day)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 31448793

Group type: EXPERIMENTAL
Intervention: Sonotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no sonotherapy)
Number of subjects: 80
Study: 29865929

Group type: EXPERIMENTAL
Intervention: Bilevel pressure (inspiratory positive airway pressure: 12 cm H2O; expiratory positive airway pressure: 8 cm H2O)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CPAP (8 cm H2O)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Respiratory muscle training (RMT)
Number of subjects: 68
Study: 26861608

Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg per day) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for a total of six cycles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Everolimus plus CHOP
Number of subjects: 30
Study: 24503413

Group type: EXPERIMENTAL
Intervention: High protein/high GI dietary group
Number of subjects: 191

Group type: COMPARATOR
Intervention: Low protein/high GI dietary group
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 191
Study: 21806467

Group type: EXPERIMENTAL
Intervention: Protraction Face Mask (PFM) therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reverse Twin-Block (RTB) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 32
Study: 21244738

Group type: EXPERIMENTAL
Intervention: Intranasal oxymetazoline (0.05% OMZ, 45 μL containing 22.5 μg of OMZ hydrochloride)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Physiological saline solution (PSS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intranasal oxymetazoline (0.05% OMZ)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (OMZ and PSS)
Number of subjects: 72
Study: 18051825

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenges (DBPCFC)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Skin prick tests with food allergens
Number of subjects: 304

Group type: COMPARATOR
Intervention: Questionnaire data
Number of subjects: 304

Group type: COMPARATOR
Intervention: Specific IgE determination (Unicap 100)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Food challenges
Number of subjects: 304
Study: 16164886

Group type: COMPARATOR
Intervention: Xenadrine EFX
Number of subjects: 10

Group type: COMPARATOR
Intervention: Advantra Z
Number of subjects: 10
Study: 12131352

Group type: EXPERIMENTAL
Intervention: Intravesical morphine (0.04 mg/kg/hour)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study: 10069634

Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh repair
Number of subjects: 200

Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 200
Study: 7733029

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic clamping
Number of subjects: 9

Group type: COMPARATOR
Intervention: Without clamping
Number of subjects: 9
Study: 2383364

Group type: EXPERIMENTAL
Intervention: 0.25% CHP cream
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.5% CHP cream
Number of subjects: 29

Group type: COMPARATOR
Intervention: 1% silver sulphadiazine (AgSD) cream
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2% CHP cream
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vehicle (control for CHP)
Number of subjects: 29
Study: 7219904

Group type: EXPERIMENTAL
Intervention: Prophylactic antihypertensive agents (placebo, hydralazine, or methyldopa)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nonrandomized group (high-risk pregnancy clinics)
Number of subjects: 63
Study: 30667500

Group type: EXPERIMENTAL
Intervention: Matched sibling donor hematopoietic stem cell transplantation (MSD‐HSCT) (n=32)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care (n=35)
Number of subjects: 67
Study: 28109057

Group type: EXPERIMENTAL
Intervention: BuMA stent
Number of subjects: 732

Group type: COMPARATOR
Intervention: Excel SES
Number of subjects: 732
Study: 25643050

Group type: COMPARATOR
Intervention: Omeprazole (40 mg once daily) administered on days 11-14 with erlotinib (150 mg) on day 15
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ranitidine (300 mg once daily) administered in the morning for 5 days, 2 h before erlotinib (150 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily) administered for 5 days, with staggered dosing of erlotinib (150 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 24
Study: 25184863

Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and dexamethasone until disease progression (535 patients)
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: 18 cycles of lenalidomide and dexamethasone (541 patients)
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Melphalan-prednisone-thalidomide (MPT) for 72 weeks (547 patients)
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and dexamethasone
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: 18 cycles of lenalidomide and dexamethasone
Number of subjects: 1623

Group type: COMPARATOR
Intervention: MPT
Number of subjects: 1623
Study: 21880545

Group type: EXPERIMENTAL
Intervention: Augmented low-Dye taping
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Replaceable ankle brace
Number of subjects: 27

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 27
Study: 20220184

Group type: EXPERIMENTAL
Intervention: Oral ivermectin (400 microg/kg)
Number of subjects: 812

Group type: COMPARATOR
Intervention: 0.5% malathion lotion
Number of subjects: 812
Study: 17600607

Group type: EXPERIMENTAL
Intervention: Olanzapine (20 mg/day and 30 mg/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 110
Study: 15992412

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: TXA
Number of subjects: 0

Group type: COMPARATOR
Intervention: EACA
Number of subjects: 0
Study: 12004990

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (0.05, 0.1, 0.2, and 0.3 microg x k(‐1) x min(‐1))
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-dose epinephrine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline QTc
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Epinephrine-induced nonsustained ventricular tachycardia
Number of subjects: 37
Study: 10661631

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 159

Group type: COMPARATOR
Intervention: Sodium phosphate (SP) solution
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 159
Study: 7788955

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg) administered intravenously over 10 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (placebo or no intervention)
Number of subjects: 18
Study: 2365041

Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline nebulized twice daily for 2 + 2 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo nebulized twice daily for 2 + 2 weeks
Number of subjects: 48
Study: 6802260

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 2 months
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 5 months
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 31342560

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 62
Study: 29158664

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (NGTS) administered for 24 weeks, with a possible uptitration to 60 mg/d after 4 weeks if BP reduction was unsatisfactory.
Number of subjects: 138
Study: 26089304

Group type: EXPERIMENTAL
Intervention: Group singing
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 258
Study: 26280719

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 112

Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 112
Study: 22251291

Group type: EXPERIMENTAL
Intervention: Causal action experience via Velcro sticky mittens
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-causal action experience via non-sticky mittens
Number of subjects: 2
Study: 19465142

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19771959

Group type: EXPERIMENTAL
Intervention: Manual compression augmented with a p‐GlcNAc fiber‐based hemostatic dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual compression alone
Number of subjects: 20
Study: 15875127

Group type: EXPERIMENTAL
Intervention: 2.5 mg x kg(‐1) propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tidal breath desflurane
Number of subjects: 80
Study: 12825997

Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% twice daily (TD)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Flutrimazole 1% once daily (OD)
Number of subjects: 84
Study: 9460336

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg/m2 i.v., day 1), 5‐fluorouracil (350 mg/m2 i.v. days 1‐3), leucovorin (300 mg i.v. days 1‐3)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2 i.v. 1‐h infusion) added to NFL regimen
Number of subjects: 128

Group type: COMPARATOR
Intervention: CMF regimen (cyclophosphamide 600 mg/m2 i.v. day 1, methotrexate 40 mg/m2 day 1; 5FU 600 mg/m2 i.v. day 1)
Number of subjects: 128
Study: 8203993

Group type: EXPERIMENTAL
Intervention: Beef (85 g of cooked beef, 8% fat)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Chicken (85 g of cooked chicken, 7% fat)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Beef and Chicken
Number of subjects: 38
Study: 3294814

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 50 mg combined with dexamethasone 1 mg in single capsules
Number of subjects: 13
Study: 12575849

Group type: EXPERIMENTAL
Intervention: Chronic plaque psoriasis patients (group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Other non-allergic skin complaints patients (group II)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Patients suspected of having allergic contact dermatitis (group III)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chronic plaque psoriasis patients with > or = 5 years old disease
Number of subjects: 200
Study: 30016935

Group type: EXPERIMENTAL
Intervention: 6 months of Dialectical Behaviour Therapy (DBT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: 12 months of Dialectical Behaviour Therapy (DBT)
Number of subjects: 240
Study: 26903390

Group type: EXPERIMENTAL
Intervention: Oral Prednisolone
Number of subjects: 416

Group type: COMPARATOR
Intervention: Oral Indomethacin
Number of subjects: 416
Study: 24485847

Group type: EXPERIMENTAL
Intervention: Combination therapy with bupropion (max 450 mg/d) and escitalopram (max 40 mg/d) for 12 weeks
Number of subjects: 245

Group type: COMPARATOR
Intervention: Escitalopram monotherapy
Number of subjects: 245

Group type: COMPARATOR
Intervention: Bupropion monotherapy
Number of subjects: 245
Study: 22568663

Group type: EXPERIMENTAL
Intervention: 40 mg immediate release (IR) oxycodone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Crushed 40 mg controlled release (CR) oxycodone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 80 mg controlled release (CR) oxycodone
Number of subjects: 19

Group type: COMPARATOR
Intervention: 40 mg controlled release (CR) oxycodone
Number of subjects: 19
Study: 20138720

Group type: EXPERIMENTAL
Intervention: High-dose levocabastine nasal spray
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Low-dose levocabastine nasal spray
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 18540482

Group type: EXPERIMENTAL
Intervention: Test product (Blastoferon)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Innovator product (Interferon beta la)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 36
Study: 15780139

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group intervention (8 weekly sessions of 2 hours each and a booster session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group intervention
Number of subjects: 0
Study: 12221168

Group type: EXPERIMENTAL
Intervention: Interferon beta1a (Rebif)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 11783208

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Traditional Chinese Medicine (TCM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Traditional Chinese Medicine (TCM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 41
Study: 8538929

Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1768560

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (0.15-0.18 mg kg-1, infused i.v.)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (infused i.v.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ICS 205-930
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6121527

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20